Cindy Juliet Cristancho Ortiz

Dr. Cindy Juliet Cristancho Ortiz

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
VGVanessa Silva Gontijo
Vanessa Silva Gontijo
FVFlávia P. Dias Viegas
Flávia P. Dias Viegas
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
MSMatheus de Freitas Silva
Matheus de Freitas Silva
CDCaio Miranda Damasio
Caio Miranda Damasio
CJClaudio Viegas Jr.
Claudio Viegas Jr.
Neurodegenerative Diseases (NDs) are progressive multifactorial neurological pathologies related to neuronal impairment and functional loss from different brain regions. Currently, no effective treatments are available for any NDs, and this lack of efficacy has been attributed to the multitude of interconnected factors involved in their pathophysiology. In the last two decades, a new approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDLs) strategy, has emerged and has been used in the design and for the development of a variety of hybrid compounds capable to act simultaneously in diverse biological targets. Based on the polypharmacology concept, this new paradigm has been thought as a more secure and effective way for modulating concomitantly two or more biochemical pathways responsible for the onset and progress of NDs, trying to overcome low therapeutical effectiveness. As a complement to our previous review article (Curr. Med. Chem. 2007, 14 (17), 1829-1852. https://doi.org/10.2174/092986707781058805), herein we aimed to cover the period from 2008 to 2019 and highlight the most recent advances of the exploitation of Molecular Hybridization (MH) as a tool in the rational design of innovative multifunctional drug candidate prototypes for the treatment of NDs, specially focused on AD, PD, HD and ALS.

26 September 2018 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MSMatheus de Freitas Silva
Matheus de Freitas Silva
KDKris Simone Tranches Dias
Kris Simone Tranches Dias
VGVanessa Silva Gontijo
Vanessa Silva Gontijo
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
CJClaudio Viegas Jr.
Claudio Viegas Jr.
Alzheimer’s disease (AD) is a progressive multifactorial neurodegenerative disorder. Currently, no effective treatment is available and this is due to multiple factors involved in pathophysiology and severity of AD. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDL) strategy, has been used to develop a variety of hybrid compounds capable to act simultaneously in diverse biological targets. The discovery of drug candidates capable of targeting multiple factors involved in AD pathogenesis would greatly facilitate in improving therapeutic strategies. This review is a complement to another review article, recently published by our group, which covered the previous period of 2005-2012, and highlights recent advances and examples of the exploitation of MTDLs approach in the rational design of novel drug candidate prototypes for the treatment of AD.

1 July 2022 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
FVFlávia P. Dias Viegas
Flávia P. Dias Viegas
VGVanessa Silva Gontijo
Vanessa Silva Gontijo
MSMatheus de Freitas Silva
Matheus de Freitas Silva
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
GFGraziella dos Reis Rosa Franco
Graziella dos Reis Rosa Franco
CJClaudio Viegas Jr.
Claudio Viegas Jr.
: Nowadays, neurodegenerative diseases (NDs), such as Parkinson’s disease (PD), Alz-heimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), repre-sent a great challenge in different scientific fields, such as neuropharmacology, medicinal chemistry, molecular biology and medicine, as all these pathologies remain incurable, with high socio-economic impacts and high costs for governmental health services. Due to their severity and multi-factorial pathophysiological complexity, the available approved drugs for clinic have not yet shown adequate effectiveness and exhibited very restricted options in the therapeutic arsenal; this high-lights the need for continued drug discovery efforts in the academia and industry. In this context, natural products, such as curcumin (1), resveratrol (2) and cannabidiol (CBD, 3) have been recog-nized as important sources, with promising chemical entities, prototype models and starting materi-als for medicinal organic chemistry, as their molecular architecture, multifunctional properties and single chemical diversity could facilitate the discovery, optimization and development of innovative drug candidates with improved pharmacodynamics and pharmacokinetics compared to the known drugs and, perhaps, provide a chance for discovering novel effective drugs to combat NDs. In this review, we report the most recent efforts of medicinal chemists worldwide devoted to the explora-tion of curcumin (1), resveratrol (2) and cannabidiol (CBD, 3) as starting materials or privileged scaffolds in the design of multi-target directed ligands (MTDLs) with potential therapeutic proper-ties against NDs, which have been published in the scientific literature during the last 10 years of research and are available in PubMed, SCOPUS and Web of Science databases.

20 October 2020 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
CDCaio Miranda Damasio
Caio Miranda Damasio
LPLetizia Pruccoli
Letizia Pruccoli
NNNathália Fonseca Nadur
Nathália Fonseca Nadur
LALuciana Luiza de Azevedo
Luciana Luiza de Azevedo
CJClaudio Viegas Jr.
Claudio Viegas Jr.

21 April 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HSHamdullah Khadim Sheikh
Hamdullah Khadim Sheikh
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
TATanzila Arshad
Tanzila Arshad
Jose M. PadronJose M. Padron
Jose M. Padron
Prof. Dr. Haroon KhanProf. Dr. Haroon Khan
Prof. Dr. Haroon Khan

17 March 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
COCindy Juliet Cristancho Ortiz
Cindy Juliet Cristancho Ortiz
MSMatheus de Freitas Silva
Matheus de Freitas Silva
LPLetizia Pruccoli
Letizia Pruccoli
NNNathália Fonseca Nadur
Nathália Fonseca Nadur
LALuciana Luíza de Azevedo
Luciana Luíza de Azevedo
CJClaudio Viegas Jr.
Claudio Viegas Jr.
A new series of eight multifunctional thalidomide–donepezil hybrids were synthesized based on the multi-target-directed ligand strategy and evaluated as potential neuroprotective, cholinesterase inhibitors and anti-neuroinflammatory agents against neurodegenerative diseases. A molecular hybridization approach was used for structural design by combining the N-benzylpiperidine pharmacophore of donepezil and the isoindoline-1,3-dione fragment from the thalidomide structure. The most promising compound, PQM-189 (3g), showed good AChE inhibitory activity with an IC50 value of 3.15 μM, which was predicted by docking studies as interacting with the enzyme in the same orientation observed in the AChE–donepezil complex and a similar profile of interaction. Additionally, compound 3g significantly decreased iNOS and IL-1β levels by 43% and 39%, respectively, after 24 h of incubation with lipopolysaccharide. In vivo data confirmed the ability of 3g to prevent locomotor impairment and changes in feeding behavior elicited by lipopolysaccharide. Moreover, the PAMPA assay evidenced adequate blood–brain barrier and gastrointestinal tract permeabilities with an Fa value of 69.8%. Altogether, these biological data suggest that compound 3g can treat the inflammatory process and oxidative stress resulting from the overexpression of iNOS and therefore the increase in reactive nitrogen species, and regulate the release of pro-inflammatory cytokines such as IL-1β. In this regard, compound PQM-189 (3g) was revealed to be a promising neuroprotective and anti-neuroinflammatory agent with an innovative thalidomide–donepezil-based hybrid molecular architecture.